Sequence: GRKKRRQRRRCG-NH2
| Experiment Id | EXP002349 |
|---|---|
| Paper | Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-mo |
| Peptide | Tat-CG analog |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 25 µg siRNA per injection |
| Rna Concentration | 25 µg |
| Mixing Ratio | N/P = 30 |
| Formulation Format | polymeric micelle |
| Formulation Components | MPEG–PCL-SS-Tat-CG + siVEGF |
| Size Nm | 100.00 |
| Zeta Mv | 12.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | S-180 tumor-bearing ICR mice |
| Administration Route | intravenous |
| Output Type | tumor growth suppression |
| Output Value | Significant tumor inhibition; reduced VEGF & CD31 |
| Output Units | |
| Output Notes | Anti-angiogenic effect; sequence-specific RNAi; no immune activation |
| Toxicity Notes | No IL-6 / IFN-α induction; well tolerated |
| Curation Notes |